Abstracts tagged "immunology"

Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Kevin Lee¹, Carrie Ye² and Shokrollah Elahi³, ¹Internal Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, University of Alberta, Edmonton, AB, Canada, ³Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…
Abstract Number: 0460 • ACR Convergence 2020
Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis
Michael Paley¹, Lynn Hassman¹, Philip Ruzycki¹, Ekaterina Esaulova¹, Grace Paley¹, Jennifer Laurent¹, Luke Springer¹, Lacey Feigl¹, Maxim Artyomov¹ and Wayne Yokoyama², ¹Washington University, Saint Louis, ²Washington University, St Louis, MO
Background/Purpose: Anterior uveitis is a form of ocular inflammation associated with rheumatologic disease and can be categorized as granulomatous or non-granulomatous. Whether different ocular manifestations…
Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Teun van Gelder¹, Robert Huizinga², Neil Solomons² and Laura Lisk³, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Nilasha Ghosh¹, Karmela Kim Chan², Bridget Jivanelli³ and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…
Abstract Number: 1931 • 2019 ACR/ARP Annual Meeting
Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq
Agnes Gardet¹, Thomas Carlile ¹, Will Chou ¹, Kejie Li ¹, Alex Pellerin ¹, Ravi Challa ¹, Will Chen ¹, Chao Sun ¹, Nathalie Franchimont ², Victoria Werth ³ and Dania Rabah ¹, ¹Biogen, Cambridge, ²Biogen, Cambridge, MA, ³Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: The immune infiltrate of skin lesions of Cutaneous Lupus Erythematosus (CLE) patients is known to be rich and complex. Single cell RNAseq (scRNAseq) is…
Abstract Number: 196 • 2018 ACR/ARHP Annual Meeting
Immunology and Immunopharmacology at Point of Care: A Quality Improvement Teaching Initiative for Rheumatology Fellows
Nina Kello¹ and Anne Davidson², ¹Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Immunology knowledge in the rheumatology community is important for a better understanding of disease pathogenesis and management, especially in an era of an expanding…
Abstract Number: 1236 • 2018 ACR/ARHP Annual Meeting
Peripheral-Blood B-Cell Subset Disturbances in Whipple’s Disease
Maelle Le Goff¹, Divi Cornec², Dewi Guellec¹, Thierry Marhadour¹, Valérie Devauchelle-Pensec¹, Sandrine Jousse-Joulin¹, Marion Herbette¹, Jean-Michel Cauvin³, Clara Le Guillou³, Yves Renaudineau⁴, Jacques-Olivier Pers⁵ and Alain Saraux¹, ¹Rheumatology, CHU Brest, Brest, France, ²Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France, ³CDC, CHU Brest, Brest, France, ⁴U1227, Université de Brest, inserm, Labex IGO, CHU de brest, Brest, France, ⁵U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France
Background/Purpose: Whipple’s disease (WD) is a rare, systemic, disease caused by the intracellular Gram-positive bacterium Tropheryma whipplei (TW). This ubiquitous commensal organism is transmitted among…
Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting
Rituximab Induced Serum Sickness: A Systematic Review
Paras Karmacharya¹, Dilli Poudel¹, Ranjan Pathak¹, Anthony Donato², Sushil Ghimire¹, Smith Giri³, Madan Aryal¹ and Clifton O. Bingham III⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA, ³Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…
Abstract Number: 3043 • 2015 ACR/ARHP Annual Meeting
IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis
Ali Ugur Unal¹, Rabia Deniz², Aysin Tulunay Virlan³, Filiz Ture Ozdemir³, Imren Aydin Tatli³, Gulsen Ozen¹, Fatma Alibaz-Oner⁴, Gonca Mumcu⁵, Tulin Ergun⁶ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁶Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey
Background/Purpose: Interleukin-17 (IL-17) has been associated with the pathogenesis of various inflammatory diseases. The aim of our study was to investigate the expression of Th17-related…
Abstract Number: 1649 • 2014 ACR/ARHP Annual Meeting
High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis
Marco Ulises Martinez-Martinez¹, Maria Daniela De Avila², Mario Perales³, Lourdes Baranda⁴, Susana Román Acosta⁵, Jaime Antonio Borjas García⁵ and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Regional Unit Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³Regional Unit of Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Regional Unit of Rheumatology and Osteoposis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Nephrology Department, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having…
Abstract Number: 910 • 2014 ACR/ARHP Annual Meeting
The Selective Sphingosine-1- Phosphate Receptor 1/5 Modulator Siponimod (BAF312) Shows Beneficial Effects in Patients with Active, Treatment Refractory Polymyositis and Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind, Randomized Trial
Katalin Danko¹, Jiri Vencovsky², Ingrid E. Lundberg³, Anthony A Amato⁴, Chester V. Oddis⁵, Maria Molnar⁶, Antonette Mallari Moher⁷, Laurence Colin⁸, Florian Muellershausen⁹, David Lee¹⁰ and Peter Gergely⁹, ¹Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²Institute of Rheumatology, Charles University, Prague, Czech Republic, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary, ⁷Translational Medicine, Novartis Institutes for Biomedical Research (former emplyee), Basel, Switzerland, ⁸Novartis Pharma, Basel, Switzerland, ⁹Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, Basel, Switzerland
Background/Purpose Polymyositis and dermatomyositis (PM/DM) comprise a heterogeneous group of chronic inflammatory muscle diseases where infiltration of lymphocytes in the skeletal muscle plays a key…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].